Dec. 3 at 5:29 PM
$LCTX Astounding Opportunity for anyone who gets it!!
OpRegen is shaping up to be one of the most compelling reversal stories in biotech. We’ve gone from a GA halt to the very real possibility that OpRegen becomes an Early GA therapy — and potentially the first true preventive or even functional cure in the category.
Think about that arc:
• A program once paused is now showing signs of doing something no approved therapy has ever achieved.
• The shift from treating advanced Geographic Atrophy to intervening earlier — where you can actually protect tissue rather than salvage what’s left — is where multi-billion-dollar value is created.
• If Early GA data continue to show structural repair, vision preservation, or meaningful functional benefit, the narrative flips overnight. We stop talking about slowing decline and start talking about changing the natural history of the disease.
